Uncovering the underlying genetic factors associated with COVID-19 host susceptibility and studying differences in immune responses may help unravel the complexities of the disease and reveal future therapeutic targets. It is crucial to identify genetic variants linked to COVID-19 susceptibility or protection and profile differences in individual immune system responses during the course of the disease. Next-generation sequencing (NGS) and microarray technologies allow researchers to interrogate host genetic variation and characterize the molecular mechanisms that drive immune responses.
The key benefits of using Illumina technologies to study host genetic variation and profile the immune response to SARS-CoV-2 include:
|Host genetics research||
|Host immune response profiling||
|Microbiome & host response||
Dr. Lee Murphy’s core lab at the University of Edinburgh applies a genomic approach to study host genetic variability in disease progression and outcome in SARS-CoV-2 hospitalized patients. The team and collaborators perform genotyping and WGS on DNA samples, as well as mRNA sequencing on the NextSeq 2000 System.View Video
The study of microbial communities found in and on the human body allows researchers to understand the role of microbes in health and disease.
A DNA sequencing method that enables comprehensive sampling of all genes in all organisms in a given complex microbial sample.
Complex diseases result from a combination of genetic and environmental factors. Array and sequencing technologies can help reveal the underpinnings of these diseases.
Expand cell and molecular biology research beyond conventional methods with next-generation sequencing.
With single-cell RNA-Seq, researchers can study cellular differences that are often masked by bulk sampling.